Characterization of NS5A and NS5B resistance-associated substitutions from genotype 1 hepatitis C virus infected patients in a Portuguese cohort

Ruben Brandão; Rute Marcelino; Fátima Gonçalves; Isabel Diogo; Ana Carvalho; Joaquim Cabanas; Inês Costa; Pedro Brogueira; Fernando Ventura; Ana Miranda; Kamal Mansinho; Perpétua Gomes

doi:10.3390/v10050223

Characterization of NS5A and NS5B resistance-associated substitutions from genotype 1 hepatitis C virus infected patients in a Portuguese cohort

Ruben Brandão, Rute Marcelino, Fátima Gonçalves, Isabel Diogo, Ana Carvalho, Joaquim Cabanas, Inês Costa, Pedro Brogueira, Fernando Ventura, Ana Miranda, Kamal Mansinho, Perpétua Gomes

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

This study is focused on the prevalent NS5 coding region resistance-associated substitutions (RASs) in DAA-naive genotype (GT)1 HCV-infected patients and their potential impact on success rates. Plasma RNA from 81 GT1 HCV-infected patients was extracted prior to an in-house nested RT-PCR of the NS5 coding region, which is followed by Sanger population sequencing. NS5A RASs were present in 28.4% (23/81) of all GT1-infected patients with 9.9% (8/81) having the Y93C/H mutation. NS5B RASs showed a prevalence of 14.8% (12/81) and were only detected in GT1b. Overall 38.3% (31/81) of all GT1 HCV-infected patients presented baseline RASs. The obtained data supports the usefulness of resistance testing prior to treatment since a statistically significant association was found between treatment failure and the baseline presence of specific NS5 RASs known as Y93C/H (p = 0.04).

Original language	English
Article number	223
Journal	Viruses
Volume	10
Issue number	5
DOIs	https://doi.org/10.3390/v10050223
Publication status	Published - May 2018

Keywords

Direct-acting antivirals
Hepatitis C virus
NS5A
NS5B
Resistance-associated substitutions

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/v10050223

Cite this

Brandão, R., Marcelino, R., Gonçalves, F., Diogo, I., Carvalho, A., Cabanas, J., Costa, I., Brogueira, P., Ventura, F., Miranda, A., Mansinho, K., & Gomes, P. (2018). Characterization of NS5A and NS5B resistance-associated substitutions from genotype 1 hepatitis C virus infected patients in a Portuguese cohort. Viruses, 10(5), Article 223. https://doi.org/10.3390/v10050223

@article{cf66c2eb8886497bbfc82bbc89819285,

title = "Characterization of NS5A and NS5B resistance-associated substitutions from genotype 1 hepatitis C virus infected patients in a Portuguese cohort",

abstract = "This study is focused on the prevalent NS5 coding region resistance-associated substitutions (RASs) in DAA-naive genotype (GT)1 HCV-infected patients and their potential impact on success rates. Plasma RNA from 81 GT1 HCV-infected patients was extracted prior to an in-house nested RT-PCR of the NS5 coding region, which is followed by Sanger population sequencing. NS5A RASs were present in 28.4% (23/81) of all GT1-infected patients with 9.9% (8/81) having the Y93C/H mutation. NS5B RASs showed a prevalence of 14.8% (12/81) and were only detected in GT1b. Overall 38.3% (31/81) of all GT1 HCV-infected patients presented baseline RASs. The obtained data supports the usefulness of resistance testing prior to treatment since a statistically significant association was found between treatment failure and the baseline presence of specific NS5 RASs known as Y93C/H (p = 0.04).",

keywords = "Direct-acting antivirals, Hepatitis C virus, NS5A, NS5B, Resistance-associated substitutions",

author = "Ruben Brand{\~a}o and Rute Marcelino and F{\'a}tima Gon{\c c}alves and Isabel Diogo and Ana Carvalho and Joaquim Cabanas and In{\^e}s Costa and Pedro Brogueira and Fernando Ventura and Ana Miranda and Kamal Mansinho and Perp{\'e}tua Gomes",

note = "Publisher Copyright: {\textcopyright} 2018 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2018",

month = may,

doi = "10.3390/v10050223",

language = "English",

volume = "10",

journal = "Viruses",

issn = "1999-4915",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "5",

}

TY - JOUR

T1 - Characterization of NS5A and NS5B resistance-associated substitutions from genotype 1 hepatitis C virus infected patients in a Portuguese cohort

AU - Brandão, Ruben

AU - Marcelino, Rute

AU - Gonçalves, Fátima

AU - Diogo, Isabel

AU - Carvalho, Ana

AU - Cabanas, Joaquim

AU - Costa, Inês

AU - Brogueira, Pedro

AU - Ventura, Fernando

AU - Miranda, Ana

AU - Mansinho, Kamal

AU - Gomes, Perpétua

PY - 2018/5

Y1 - 2018/5

N2 - This study is focused on the prevalent NS5 coding region resistance-associated substitutions (RASs) in DAA-naive genotype (GT)1 HCV-infected patients and their potential impact on success rates. Plasma RNA from 81 GT1 HCV-infected patients was extracted prior to an in-house nested RT-PCR of the NS5 coding region, which is followed by Sanger population sequencing. NS5A RASs were present in 28.4% (23/81) of all GT1-infected patients with 9.9% (8/81) having the Y93C/H mutation. NS5B RASs showed a prevalence of 14.8% (12/81) and were only detected in GT1b. Overall 38.3% (31/81) of all GT1 HCV-infected patients presented baseline RASs. The obtained data supports the usefulness of resistance testing prior to treatment since a statistically significant association was found between treatment failure and the baseline presence of specific NS5 RASs known as Y93C/H (p = 0.04).

AB - This study is focused on the prevalent NS5 coding region resistance-associated substitutions (RASs) in DAA-naive genotype (GT)1 HCV-infected patients and their potential impact on success rates. Plasma RNA from 81 GT1 HCV-infected patients was extracted prior to an in-house nested RT-PCR of the NS5 coding region, which is followed by Sanger population sequencing. NS5A RASs were present in 28.4% (23/81) of all GT1-infected patients with 9.9% (8/81) having the Y93C/H mutation. NS5B RASs showed a prevalence of 14.8% (12/81) and were only detected in GT1b. Overall 38.3% (31/81) of all GT1 HCV-infected patients presented baseline RASs. The obtained data supports the usefulness of resistance testing prior to treatment since a statistically significant association was found between treatment failure and the baseline presence of specific NS5 RASs known as Y93C/H (p = 0.04).

KW - Direct-acting antivirals

KW - Hepatitis C virus

KW - NS5A

KW - NS5B

KW - Resistance-associated substitutions

UR - http://www.scopus.com/inward/record.url?scp=85046272851&partnerID=8YFLogxK

U2 - 10.3390/v10050223

DO - 10.3390/v10050223

M3 - Article

C2 - 29701642

AN - SCOPUS:85046272851

SN - 1999-4915

VL - 10

JO - Viruses

JF - Viruses

IS - 5

M1 - 223

ER -

Characterization of NS5A and NS5B resistance-associated substitutions from genotype 1 hepatitis C virus infected patients in a Portuguese cohort

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this